

ForPatients

by Roche

Hepatitis B Virus Healthy Volunteers

A Study in Healthy Volunteers and in Participants With Chronic Hepatitis B to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7020531

Trial Status
Completed

Trial Runs In
8 Countries

Trial Identifier
NCT02956850 2016-003723-38
NP39305

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This sponsor-open, investigator- and participant-blinded, multi-center study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of RO7020531 in healthy participants and in participants with chronic hepatitis B. Part I will be conducted in two portions: Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) which will include only healthy volunteers. Part II will commence after completion of the MAD portion of Part I and will include only Chronic Hepatitis B (CHB) participants.

Hoffmann-La Roche
Sponsor

Phase 1
Phase

NCT02956850 2016-003723-38 NP39305
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>= 18 Years & <= 65 Years

Healthy Volunteers
Accepts Healthy Volunteers
